LEE'S PHARMACEUTICAL HOLDINGS LIMITED

RegeneRx and Lee's Pharm to Accelerate RGN-259 Development in China

Retrieved on: 
Tuesday, March 26, 2019
Ophthalmic, Pharmaceutical industry in China

and HONG KONG, March 26, 2019 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Limited ("Lee's Pharm"), a Hong Kong-based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications.

Key Points: 
  • and HONG KONG, March 26, 2019 /PRNewswire/ --RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings Limited ("Lee's Pharm"), a Hong Kong-based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications.
  • Earlier this year Lee's Pharm made a US$200,000 investment in RegeneRx as part of a convertible debt transaction, along with RegeneRx's management and board of directors.
  • "With our recently created subsidiary, China Ophthalmology Focus Limited, and our new ophthalmic manufacturing facilities, we are now well-positioned to accelerate development of RGN-259 in China for dry eye syndrome and other ophthalmic disorders.
  • China Ophthalmology Focus Limited ("COPF"), a subsidiary of Lee's Pharm, is a company specialized in the development, manufacturing and marketing of ophthalmic topical drugs.